
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's Innovative Medicine segment achieved revenues of $15.20 billion in the second quarter of 2025, surpassing expectations and reflecting a robust growth trajectory, especially in oncology, immunology, and neurology. The company raised its full-year 2025 sales guidance by approximately $2.4 billion to a range of $93.2 to $93.6 billion, benefiting from both operational strengths and favorable currency fluctuations. With management expressing confidence in stronger operational sales growth in the second half of 2025 and into 2026, there is a positive outlook for continued financial performance, contributing to recent stock price gains.
Bears say
The financial outlook for Johnson & Johnson is overshadowed by declining revenues in critical segments, with Orthopedics sales of $2.31 billion showing a year-over-year operational decline of 1.6%, compounded by competitive pressures in the U.S. MedTech market and inventory dynamics. The pharmaceutical division is also facing a substantial risk of reduced organic revenue growth, highlighted by potential contributions falling below $57 billion by 2025 due to loss of exclusivity for key drugs and the need to effectively navigate an evolving product pipeline. Additionally, ongoing litigation costs and challenges in M&A integration pose further threats to the company's financial stability and predictability, raising concerns about future growth prospects.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares